While it was heralded with much promise, the anti-malarial drug hydroxychloroquine commanded much attention in the early dates of the COVID-19 pandemic. From the primary repurposed…
Merck’s quest for the development of treatments targeting COVID-19 has increasingly disappointed all, but the big bet stands right before them—and all of society. If…
AB Science SA (Euronext – FR0010557264 – AB), together with the University of Chicago, today announce the signing of an exclusive licensing agreement for conducting research…
Vaccination programs targeting COVID-19 now unfold around the world. While over time this will have a profound impact on the pandemic, vaccines will never represent…
EIDD-2801, the Merck drug now known as Molnupiravir, can be administered orally as a pill in an outpatient setting. The big gap that TrialSite advocates drug…
The eastern African nation of Rwanda appears to be joining dozens of others nations worldwide and accepting Favipiravir as a treatment for COVID-19. The oral,…
Appili Therapeutics Inc. (TSX: APLI, OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases, today announced that its…
Based on preclinical research in cell cultures and animals, a team of investigators at the University of Nottingham in England and collaborators find that thapsigargin,…
A research team led by the prestigious University of California, San Francisco (UCSF) reveals that a drug known as Aplidin absolutely destroys the SARS-CoV-2 virus…
Yet another nation has opted to embrace the antiviral drug Favipiravir (Avigan) as a treatment for early onset COVID-19. Approved in Japan for influenza (and…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.
